Shopping Cart
- Remove All
- Your shopping cart is currently empty
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $157 | In Stock | |
5 mg | $428 | In Stock | |
10 mg | $695 | In Stock | |
25 mg | $1,060 | In Stock | |
50 mg | $1,430 | In Stock |
Description | Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells. |
In vitro | Clivatuzumab exhibits high specificity for pancreatic ductal adenocarcinoma (PDAC), showing minimal reactivity towards normal and benign non-tumorous pancreatic tissues. Although it demonstrates limited reactivity (approximately 10% of all samples) towards adenocarcinomas in certain other organs such as the stomach, colon, and lungs [1]. |
Molecular Weight | 145.42 kDa |
Cas No. | 1622075-09-5 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.